T-knife
Manufacturing · Germany · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Robert-rossle-str 10, Berlin, Berlin, 13...Phone Number
+49 3094892432Website
www.t-knife.comRevenue
$8.5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About T-knife
Founded in 2018 and headquartered in Berlin, Germany, T-knife is a spin-off from Max-Delbruck Center for Molecular Medicine with support from Charité University Hospital to provide novel, sophisticated T cell receptor-based therapeutics to market.Explore more
T-knife Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is T-knife your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once T-knife has new funding data
Earning: See what the market has to say on T-knife recently announced quarterly report
Click to see if T-knife had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Check if T-knife has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when T-knife launches new products
Check out if T-knife is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at T-knife
T-knife, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Reach out to Masked Content who joined T-knife as Masked Content
Find more new buyers
Company Profile Activity
Activity Insights
T-knife is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
T-knife is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about T-knife.
T-knife financials insights
Gather financial insights about T-knife, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Series A
$77.2M
2021
Series B
$110M
T-knife Tech Stack
A closer look at the technologies used by T-knife
See more technologies
Most Recent Scoops
Project
Product Management, Legal Affairs, Governmental Affairs & Regulation, Medical Research, Pharmaceuticals, Clinical Operations, Regulations
Left Company
Executive Move
T-knife has announced that Megan Baierlein, Senior Vice President & Chief Operating Officer, has left the organization to join Third Rock Ventures (Newco) as Chief Operating Officer.
New Hire
Executive Move
Left Company
Executive Move
New Hire
Executive Move
T-knife News & Media
T-knife Therapeutics Presents Preclinical Data on PRAME-Targeted TK-6302 Highlighting its Potential as a Promising, Category-leading Therapy at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
-- Comprehensive TK-6302 data demonstrate preclinical efficacy and safety, supporting clinical readiness, alongside established scalable manufacturingT-knife Therapeutics Announces Four Upcoming Data Presentations on PRAME-Targeted TK-6302 at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
-- Posters will review product characterization and manufacturing data on T-knife’s lead program, TK-6302, a supercharged PRAME T cell receptor therapy that is advancing towards the clinic, with the filing of a Clinical Trial Application planned in Q4 2025 -- PRAME is a validated target and is expressed in cancers of the skin, uterus, ovaries, lungs, breasts, esophagus, kidneys, cervix, and head & neckT-knife Therapeutics Presents Preclinical Data Highlighting the Transformative Potential of the MyT™ Platform to Discover and Develop Next-Generation TCR Therapies to Treat Solid Tumors at the European Society of Gene & Cell Therapy (ESGCT) 2025 Annual Congress
-- Integrating a computational workflow that leverages multi-omics data with a proprietary, humanized in vivo screening platform, T-knife identified highly immunogenic solid-tumor antigens not previously recognized as functional
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding T-knife
Sign Up For FreeTo access detailed company insights
Founded in 2018 and headquartered in Berlin, Germany, T-knife is a spin-off from Max-Delbruck Center for Molecular Medicine with support from Charité University Hospital to provide novel, sophisticated T cell receptor-based therapeutics to market.... Read More
